Title
Real time assays for quantifying cytotoxicity with single cell resolution.

Permalink
https://escholarship.org/uc/item/35c0203c

Journal
PLoS One, 8(6)

Authors
Hsiao, Sonny
Liu, Hong
Holstlaw, Taylor
et al.

Publication Date
2013

DOI
10.1371/journal.pone.0066739

Peer reviewed
Real Time Assays for Quantifying Cytotoxicity with Single Cell Resolution

Sonny C. Hsiao¹*, Hong Liu²*, Taylor A. Holstlaw¹, Cheng Liu², Catherine Y. Francis¹, Matthew B. Francis³,⁴
¹ Adheren, Inc., Berkeley, California, United States of America, ² Eureka Therapeutics, Emeryville, California, United States of America, ³ Department of Chemistry, University of California, Berkeley, California, United States of America, ⁴ Materials Sciences Division, Lawrence Berkeley National Laboratories, Berkeley, California, United States of America

Abstract

A new live cell-based assay platform has been developed for the determination of complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC), and overall cytotoxicity in human whole blood. In these assays, the targeted tumor cell populations are first labeled with fluorescent Cell Tracker dyes and immobilized using a DNA-based adhesion technique. This allows the facile generation of live cell arrays that are arranged arbitrarily or in ordered rectilinear patterns. Following the addition of antibodies in combination with serum, PBMCs, or whole blood, cell death within the targeted population can be assessed by the addition of propidium iodide (PI) as a viability probe. The array is then analyzed with an automated microscopic imager. The extent of cytotoxicity can be quantified accurately by comparing the number of surviving target cells to the number of dead cells labeled with both Cell Tracker and PI. Excellent batch-to-batch reproducibility has been achieved using this method. In addition to allowing cytotoxicity analysis to be conducted in real time on a single cell basis, this new assay overcomes the need for hazardous radiochemicals. Fluorescently-labeled antibodies can be used to identify individual cells that bear the targeted receptors, but yet resist the CDC and ADCC mechanisms. This new approach also allows the use of whole blood in cytotoxicity assays, providing an assessment of antibody efficacy in a highly relevant biological mixture. Given the rapid development of new antibody-based therapeutic agents, this convenient assay platform is well- poised to streamline the drug discovery process significantly.

Introduction

Antibodies are able to recognize and destroy targeted cells, such as those corresponding to tumors or viral infections, through complement dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC) [1,2]. These pathways are believed to be involved in the mechanism of action for many antibody-based therapeutics, and thus it is imperative to be able to assess the ability of an immunoglobulin drug candidate to elicit these responses. Cell lysis by the CDC or ADCC process is typically measured for a bulk population by monitoring the release of chromium-51 ($^{51}$Cr) [3] that had been previously taken up by the cells, or by the release of lactic acid dehydrogenase (LDH) [4,5]. The measurement of cell viability has also been successfully measured for a CDC experiment using a soluble MTT reporter [6,7]. Although widely used, however, all of these methods have their shortcomings. $^{51}$Cr is radioactive, expensive, and adds disposal difficulties, which has led to the popularity of the LDH release method. However, this method can lead to large sample errors in ADCC assays since both the target and effector cells contain LDH [8,9]. All of the available methods provide an average toxicity value for a whole population of cells, providing no information about individual cell behavior. Finally, these techniques require the evaluation of relatively large cell populations to obtain usable reproducibility. This can be especially problematic in cases where targeted cells are in short supply, such as the use of blood samples from specific leukemia patients.

To address these limitations while providing increased amounts of diagnostic information for a particular cell-treatment combination, we report herein a new cytotoxicity assay that can be used to evaluate the response of individual cells to antibodies and other drug candidates. The technique uses fluorescence microscopy and automated image processing to determine the number of both living and dead cells with a high degree of precision, and only requires inexpensive and readily available dyes. The method can be used in real time to provide temporal information about cytotoxicity, and it can be used to identify cells that bear the targeted receptor, and yet resist the CDC and ADCC mechanisms. It can also clearly distinguish between targeted and effector cells, providing accurate cytotoxicity data using the complex samples of peripheral blood mononuclear cells (PBMCs) and even whole blood. In this work, this analysis method is demonstrated using leukemia and lymphoma cells and a known therapeutic...
antibody. However, the generality of the method should allow its
extension to the evaluation of many different tumor cell types and
drug candidates.

Results and Discussion

Creating Live Cell Arrays through DNA Adhesion

A key aspect of this technique is the attachment of living cells to
analysis surfaces through the use of DNA-based adhesion [10–14].
In this approach, synthetic DNA strands bearing NHS esters are
covalently conjugated to proteins on the surfaces of the target cells,
as outlined schematically Fig. 1a. Previous studies have indicated
that the modification procedure results in the addition of
~100,000 DNA strands, with no notable effects on cell morphol-
ogy or undesired pathway activation. Upon exposure to glass
surfaces bearing the sequence complements, the cells adhere
through DNA hybridization, Fig. 1b. This provides a robust
linkage that can be maintained for days if needed, while
maintaining excellent cell viability. In previous studies using
AFM, we have measured the strength of adhesion to be ~800 pN
[14]. The use of this strategy is particularly important for cells of
the immune system, as they are naturally non-adherent and thus
cannot be bound using integrin-targeting strategies. Through the
use of commercially available pre-printed platforms, large areas
with high cell densities can be prepared (Fig. 1c), as well as
ordered microarrays comprising small cell clusters (Fig. 1d). Both
96-well plate and 8-well chamber slide formats are currently
available, and can be used interchangeably in the experiments
described below. Following generation of the arrays, a brief rinse
with PBS removes any non-bound cells. In the case of the cell
microarrays, the use of this procedure provides 5000±550 (11% standard deviation for N=5 samples) cells per well.

For experiments involving ADCC or whole blood toxicity assays
(see below), the targeted cells are also labeled with fluorescent Cell
Tracker dyes during the DNA modification step. This labeling is
not necessary for CDC assays, as no additional cells are added in
these procedures.

CDC Assays using Live Cell Arrays

To explore the use of these DNA-captured live cell populations
in the context of screening therapeutic antibody candidates,
different concentrations of a humanized anti-CD20 antibody
produced in CHO cells, and referred to as α-CD20 herein [15–
17] were applied to the wells of chamber slides containing arrays
of Jeko-1 lymphoma cells. Human serum (Quidel Corporation,
San Diego, CA) was then added to each well of the assay. After
4 h, the extent of CDC was determined by exposing the cells to a
solution of propidium iodide (PI). By comparing bright field and
fluorescence images, the number of living and dead cells could be
quantitated easily, Fig. 2a (also see close-up image in Fig. 3a).
Some insoluble PI stain was observed as large diffuse aggregates,
but these were easily distinguished from the cells. Triplicate
experiments indicated excellent plate-to-plate reproducibility,
with 5% variability or less for all concentrations investigated, Fig. 2b.
A dose-dependent response was observed, with peak toxicity seen
at the highest α-CD20 concentration (100 μg/mL). Low levels of
cell death, ranging between 0% to 3%, were observed when Jeko-1
cells were incubated with a negative control antibody (NC Ab),
which had no affinity towards Jeko-1 cells. This result also verified
that the DNA-based adhesion method itself did not lead to losses
in cell viability. The overall results of this assay compared well to
the previously published EC₅₀ values for other anti-CD20
antibodies (such as Rituxan), which range from 5–70 μg/mL
[18–21].

Time-lapsed Images of the CDC Process

Because this assay has the ability to track specific cells for the full
duration of the experiment, it allows one of the first real-time
explorations of the CDC process. To do this, an array of DNA-
immobilized Jeko-1 cells was exposed to α-CD20, serum, and PI
throughout the incubation process. Time-lapsed images were
acquired using an ImageXpress Micro (IXM) Automatic Imager
(Molecular Devices) and merged into a movie (see Video S1). Cell
death was observed as early as 10 min using the dose of α-CD20
(10 μg/mL), and was found to plateau after 2 h, Fig. 2c. The
ability to acquire temporal information about the CDC process
is highly useful for the evaluation of new antibody candidates, as one
experiment can provide comparative information at many
different time points. This allows for much greater efficiency in
these assays by minimizing the number of duplicate experiments
that must be run for each antibody candidate. In contrast, both the
51Cr- and the LDH-release assays are most suited for providing
data at single endpoints.

Identification of CDC Resistant Target Cells using a
Fluorescent Antibody

The ability to conduct cytotoxicity assays on an individual cell
basis provides new opportunities for the identification of drug-
resistant cells [22–25]. Live cells can be removed from the DNA-
based arrays very quickly through the addition of DNase, or
somewhat more slowly through the addition of competing
complementary DNA strands. Either technique provides live cells
that could be used for sequencing, transcriptional profiling, or
further culture.

This method is particularly informative when fluorescent
antibodies are used, as cells that lack the targeted receptor can
be distinguished from those that resist the CDC pathway through
active mechanisms. As an example, FITC-labeled α-CD20 [26]
was used to identify the receptor-positive target cells. After
incubation with serum, followed by propidium iodide staining,
comparison of the PI (red, Fig. 3a) and FITC-α-CD20 (green,
Fig. 3b) channels revealed a number of cells that were recognized
by the antibody, but nonetheless remained alive during the 4 h
incubation period. This variation demonstrates the ability of this
assay platform to identify individual response behaviors even
within a single population of cultured cells. It is widely appreciated
that much greater cell-to-cell variation is present in primary tumor
tissue, and thus this method should be invaluable to groups
investigating the molecular basis of drug resistance.

Testing Antibody Specificity using Live Cell Arrays

An important consideration for the development of any
therapeutic antibody is the level of cytotoxicity specificity it can
achieve for its cellular target. This can easily be determined using
the same assay platform with fluorescence imaging at multiple
wavelengths. For example, a population of Jeko-1 (a CD20-positive
cell line) cells was labeled with Cell Tracker green and combined
with a population of Jurkat T-leukemia cells (a CD20-negative cell
line) that was labeled with Cell Tracker blue. The mixture of cells
was then bound to an array of 40 μm DNA capture spots, Fig. 4.
The CDC protocol described above was used, and the dead cells
were then stained with PI. There was a clear overlap between
the green (targeted) cells and the red PI stain (represented by yellow in
the merged image). In contrast, the blue Jurkat cells showed little
overlap with the PI stain, indicating the high degree of specificity
of the α-CD20 antibody for the CD20 receptor that only the Jeko-
1 cells possess. If desired, similar experimental configurations
could be designed to verify the specificity of antibody binding by
first labeling the immunoglobulin candidates with fluorescent dyes, as described above.

**ADCC Assays using Live Cell Arrays**

A second and highly important mechanism of cytotoxicity involves the recognition of antibody Fc regions by natural killer cells. This antibody-dependent cellular cytotoxicity process is particularly difficult to carry out on a single cell basis because it is difficult to distinguish the targeted cells from effector cells supplied as mixtures of peripheral blood mononuclear cells (PBMCs). By binding only the targeted cells to the analysis surface, in addition to labeling them with cytoplasmic dyes, the DNA-based cell array method can lead to more accurate determinations of this process than were previously possible. Triplicate samples of fluorescently labeled Jeko-1 cells (blue) were arrayed in chamber slides and then exposed to the \(\alpha\)-CD20 antibody in varying concentrations for 30 min. Suspensions of PBMCs (AllCells, Inc., 25:1 E/T ratio) were then added directly to the samples and incubated at 37°C for 16 h. Following the addition of the PI stain, fluorescence imaging again revealed the ratio of dead to living cells, Fig. 5a–d. Quantitation of the resulting samples again revealed a dose-dependent response (Fig. 5e), with excellent plate-to-plate reproducibility (<7% variation). Nearly 100% cytotoxicity was observed at the highest \(\alpha\)-CD20 concentration (100 \(\mu\)g/mL). Low levels of killing, ranging between 5% and 10%, were detected after Jeko-1 cells were incubated with a negative control antibody (NC Ab) acquired from Eureka Therapeutics, Inc. The observed ADCC EC50 value for \(\alpha\)-CD20 compared well to the previously published values of 0.02–0.5 \(\mu\)g/mL for Rituxan [18–21]. These results highlight the value of being able to identify both the living and the dead target cells in a complex mixture to obtain accurate toxicity statistics. This is difficult to do using other methods. It is also possible to conduct the same assay for resistant cells in the context of an ADCC experiment when fluorescent antibodies are used, as described above for CDC assays. Similar results were obtained when primary B-chronic lymphoblastic leukemia cells were used instead of Jeko-1 cells, Fig. 5f.

**Cytotoxicity Assays Conducted in Whole Blood**

While the ability to conduct CDC and ADCC assays independently is important for determining the mechanism of cytotoxicity, it would also be highly advantageous to evaluate the efficacy of a therapeutic antibody candidate using whole blood samples. This would effectively combine complement and cellular toxicity activity, and would provide the most relevant information regarding the specific response that a given patient would have.
When combined with the ability of the cellular toxicity array method to provide accurate data using very small cell samples, this could lead to the personalized screening of antibody-based therapies against the cells obtained from a single patient. Currently...
the only feasible way to evaluate cytotoxicity in whole blood is the use of flow cytometry [27], which suffers from low sample throughput and requires significantly larger numbers of cells.

To demonstrate this process, we first prepared a series of wells containing fluorescently labeled target cells. Large DNA capture spots were used in these assays, which removed one of the washing steps from the procedure because all of the DNA-labeled cells were bound by the plate surface. Triplicate samples (10,000 cells each) were prepared in a 96-well plate, along with 500 nM PI stain. CD20 was then added in varying concentrations. To each well were added 180 μL of freshly drawn human blood (AllCells, Inc.). After 16 h of incubation at 37°C, the samples were visualized directly. Because the target cells are all immobilized in the same focal plane, their fluorescence could be measured directly even without removing the blood cells in the suspension above. As shown in Fig. 6a–c, clear detection of the targeted cells (both alive and dead) was possible. A dose-dependent response was again observed, with only 5–7% well-to-well variance. An EC50 value of 0.3 μg/mL was obtained (Fig. 6d), which was in line with that obtained in the CDC and ADCC assays. Thus, accurate data could be obtained without the use of PBMCs, which are typically only available in limited quantities. While CDC and ADCC assays will likely remain the principal means of evaluating new antibody candidates, this new whole blood assay can, in parallel, provide information on the performance of the agents in a more realistic sample matrix.

### Conclusion

There are number of significant advantages of this new cytotoxicity assay platform, including the use of smaller sample sizes, the immobilization of the cells through stronger linkages to minimize cell losses during the rinsing steps, the ability to obtain real-time data, and the ability to capture specific live cells that resist a given treatment method. Unlike most cytotoxicity assays, which indirectly relate cell death to the release of cytoplasmic contents into a bulk solution, this technique allows the researcher to obtain more accurate cytotoxicity data by directly reporting the number of living and dead cells. Such single-cell analysis capabilities [28,29] were critically important to achieving the high precision observed in these assays, enabled the use of much smaller cell samples, and were required for the analysis of cytotoxicity in whole blood. This is particularly powerful when combined with the automated imaging and data analysis platforms that are available from a number of different vendors. The 96-well plate format allows replicate samples to be compared under uniform experimental conditions, as evidenced by the low variability between the wells in these experiments. Finally, the compatibility of the DNA-based adhesion strategy with both adherent and non-adherent cells allows these platforms to be extended for use in many different types of drug screens.

High-throughput cytotoxicity assays, such as these, could help to usher in a new era of personalized medicine. The small sample
sizes and rapid analyses associated with this platform allow many more combinations of cell lines and drug candidates to be evaluated than were previously possible. This can facilitate the evaluation of combination therapies, in which two or more antibodies that target complementary receptor groups are used in concert. As each well requires 10,000 target cells or fewer, patient biopsies and primary leukemia cells isolated from blood samples can provide many more data points. This individualized screening process becomes particularly powerful when combined with the ability to evaluate the efficacy of a given agent in a patient’s own blood, likely allowing a more accurate prediction of how a therapeutic agent will perform once administered.

---

**Materials and Methods**

**Preparation of Cell Microarrays**

Cytolink cell microarray products were obtained from Adheren, Inc., in either 8-well chamber slide or 96-well microtiter plate formats. The cell microarrays were prepared following the protocol provided by the manufacturer. In brief, 60 μL of a 0.39 μM solution of DNA with a thiol at the 5’ end was reacted with 0.2 mg of succinimidyl-[N- maleimidopropionamido]-hex-ethylenglycol] (NHS-PEO6-maleimide) (Pierce) in 40 μL of DMSO to obtain 1 mL of a 23.4 μM NHS-DNA solution in PBS (pH 7.2). The target cells, which had been rinsed twice with PBS before use, were then incubated with the NHS-DNA solution for 30 min at RT. Cell Tracker Blue or Green (Invitrogen, final concentration of 500 nM) was added along with the NHS-DNA
Measuring Cytotoxicity with Single Cell Resolution

a: Raji cells  b: PI fluorescence  c: Raji and PI merge

0.01 µg/mL α-CD20

0.1 µg/mL α-CD20

1 µg/mL α-CD20

100 µg/mL NC Ab

d

% cell death

0.01 0.1 1 10 100

[α-CD20], µg/mL

control antibody
solution if fluorescent labeling was needed. Following this, the cells were washed twice with PBS containing 1% FBS, and resuspended in a fresh portion of 1% FBS in PBS. In the case of 8-well chamber slides, a suspension of $1 \times 10^5$ cells/mL was prepared, and 100 μL were added to each well. After 20 min of incubation at RT, the samples in either format were washed twice with PBS/1% FBS to remove any unbound cells. The cell microarrays were fully formed at this point, and could be observed and counted by microscopy or by using an automated imager.

For experiments that did not require the use of cell microarrays, 50 μL aliquots of the DNA-modified cells ($5 \times 10^5$ cells/mL) were added to each DNA complement-coated well. After 20 min of incubation at RT, all of the cells were bound to the surface. No further rinses were required before the addition of antibody solutions.

**Antibodies**

The antibodies used in the CDC and ADCC assays were humanized anti-CD20 IgG1 (referred to as “α-CD20”) and ET901, which was raised against a proprietary non-mammalian target (used as a control, listed as “NC Ab”). Both were produced in CHO cells and obtained from Eureka Therapeutics as solutions targeted (used as a control, listed as “NC Ab’’). Both were produced in CHO cells and obtained from Eureka Therapeutics as solutions.

**Effector Cell Preparation**

The lymphoma cell line Jeko-1 was chosen for the ADCC and CDC experiments, and Jurkat leukemia T-cells (which are CD20 negative) were chosen as a control cell line. Whole blood cytotoxicity assays used Raji lymphoma cells. All cell lines were obtained from the ATCC and maintained in RPMI 1640 culture medium, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4 mM L-glutamine, and 500 IU/mL penicillin/streptomycin. Cell viability was determined by 0.4% trypan blue exclusion before use.

**Target Cell Preparation**

The lymphoma cell line Jeko-1 was chosen for the ADCC and CDC experiments, and Jurkat leukemia T-cells (which are CD20 negative) were chosen as a control cell line. Whole blood cytotoxicity assays used Raji lymphoma cells. All cell lines were obtained from the ATCC and maintained in RPMI 1640 culture medium, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4 mM L-glutamine, and 500 IU/mL penicillin/streptomycin. Cell viability was determined by 0.4% trypan blue exclusion before use.

**ADCC Assays**

Jeko-1 lymphoma cells were immobilized on Adheren Cytolink cell microarrays in 8-well chamber slides. Before use, the Jeko-1 cells were stained fluorescent green using Cell Tracker Green. The harvested cells were labeled with Cell Tracker Green or Cell Tracker Blue in accordance with the manufacturer’s instructions. The target cells were then immobilized on Cytolink cell microarray chamber slides or in 96-well plates, as described above.

**CDC Assays**

Jeko-1 lymphoma cells were immobilized on Cytolink cell microarrays in 8-well chamber slides. The assay buffer consisted of RPMI +0.1% BSA +20 mM HEPES. The antibody was dissolved in the assay buffer to form a series of stock solutions at twice the intended final concentrations (which resulted in 0.01 to 100 μg/mL concentrations after dilution in the sample wells). After the Jeko-1 cells had been bound by the microarray and the free cells had been removed by rinsing, 200 μL of the antibody solution was added to each chamber of the slide. The resulting samples were incubated at 37°C for 20 min. Fresh human PBMCs in assay buffer were prepared at a concentration of 1 × 10^6 cells/mL. The desired volume of PBMCs was added to the wells to create a ratio of 25:1 PBMCs to Jeko cells (E/T ratio = 25:1). The chamber slide was then incubated at 37°C with 5% CO2 for 16 h. The samples were washed gently three times to remove most of the unbound effector cells, although this step was not necessary in all cases. Cell viability was analyzed using PI staining (500 nM final concentration) in assay buffer was added to each chamber of the slide. Each sample was then incubated at 37°C with 5% CO2 for 4 h. Cell viability was analyzed using a propidium iodide (PI) solution (final concentration of 500 nM in each well), and imaged using a fluorescence microscope or an ImageXpress Micro (IXM) automated imager. The PI solution was added at the end of the experiments, or it was added with the serum if real-time images were to be collected.

**Antibody Resistance Assays**

Jeko-1 lymphoma cells were immobilized on Cytolink cell microarrays in 8-well chamber slides. The assay buffer consisted of RPMI +0.1% BSA +20 mM HEPES. The FITC labeled α-CD20 antibody was dissolved in the assay buffer to form a stock solution at twice the desired final concentration (which resulted in 100 μg/mL after dilution in the sample wells). After the Jeko-1 cells had been bound by the microarray and the free cells had been removed by rinsing, 200 μL of the antibody solution was added to each well of the chamber slide. The resulting samples were incubated on ice for 60 min. After this time, 200 μL of prepared 30% (v/v) human serum solution in assay buffer was added to each chamber of the slide. Each sample was then incubated at 37°C with 5% CO2 for 4 h. Cell viability was analyzed using a propidium iodide (PI) solution (final concentration of 500 nM in each well), and imaged using a fluorescence microscope or an ImageXpress Micro (IXM) automated imager.

**Measuring Cytotoxicity with Single Cell Resolution**

The scale bar in each image represents 100 μm. (a) Raji lymphoma cells were labeled with a blue Cell Tracker dye and then immobilized. Varying concentrations of α-CD20 were added, followed by freshly drawn human blood. The targeted cells could be easily identified using fluorescence microscopy, even in the presence of a large excess of blood cells. (b) After 16 h, the amount of cell death could be quantified using a PI stain (red). (c) A merged image allowed the ratio of living (blue) to dead (purple) targeted cells to be determined. (d) The level of whole blood cytotoxicity is shown for α-CD20, in addition to a control antibody (red point). The error bars indicate the standard deviation of two replicate experiments.

doi:10.1371/journal.pone.0066739.g006
concentration), followed by cell counting with a microscopy imager (IXM) or a fluorescence microscope.

Whole Blood Cytotoxicity Assays
Raji lymphoma cells were immobilized on Adheren Cytolink 96-well plates. In these experiments, the microarray cell patterns were not used. The target cells were stained fluorescent green before use with Cell Tracker Green. The assay buffer consisted of RPMI +10% FBS +1% penicillin/streptomycin (Life technologies). The antibody was dissolved in assay buffer to form a series of solutions at ten times the intended final concentrations (which resulted in 0.025 to 100 μg/mL concentrations after dilution in the sample wells). After the cells had bound the DNA-coated well plates (no rinsing was required), 20 μL of antibody solution was added to each of the sample wells. The plate was then incubated at 37°C for 20 min. A sample of heparinized fresh human whole blood was obtained from Allcells, Inc. To each sample well was added 180 μL of whole blood, and the resulting plate was then incubated at 37°C with 5% CO2 for 16 h. After this time, cell viability was analyzed directly (without rinsing away the effector cells) using a PI stain (500 nM final concentration). The cells were then imaged using a microscopy imager (IXM) or a fluorescence microscope.

Supporting Information
Video S1 Time-lapsed images of the CDC process. Cell death was monitored for 4 hours using the dose of α-CD20 (10 μg/mL). (WMV)

Acknowledgments
We wish to acknowledge Dr. Paul Lam and the UC Berkeley Biomolecular Nanotechnology Center for useful suggestions and support of material and instruments.

Author Contributions
Conceived and designed the experiments: SCH HL CL CYF MBF. Performed the experiments: SCH TAH HL. Analyzed the data: SCH HL CL CYF MBF. Contributed reagents/materials/analysis tools: CL MBF. Wrote the paper: SCH TAH HL CL CYF MBF.

References
1. Wang SY, Weiner G (2008) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Expert Opin Biol Ther 8: 759–768.
2. Dalle S, Thiblemont C, Thomas L, Dumontet C (2008) Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 8: 525–532.
3. Brunner KT, Mauel J, Cerottini JC, Chappuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14: 181–196.
4. Korszeniewski C, Callewaert DM (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64: 313–320.
5. Wu L, Adams M, Carter T, Chen R, Muller G, et al. (2008) Lenalidomide cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14: 4650–4657.
6. Johann S, Blümel G, Lipp M, Förster R (1995) A versatile flow cytometry-based assay for the determination of short- and long-term killer cell activity. J Immunol Methods 183: 209–216.
7. Khattak SF, Spatara M, Roberts L, Roberts SC (2006) Application of colorimetric assays to assess viability, growth and metabolism of hydrogel-encapsulated cells. Biotechnol Lett 2: 1361–1370.
8. Gerlier D, Thomasset SJ (1986) Use of MTT colorimetric assay to measure cell activation. Immuno Methods 94: 57–63.
9. Gupta P, Goldenberg DM, Ross EA, Carillo TM, Byrd JC, et al. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14: 6985–6991.
10. Wang SY, Weiner G (2008) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Expert Opin Biol Ther 8: 759–768.
11. Koscin C, Callaghan M (2000) Rituximab: a new monoclonal antibody therapy for non-Hodgkin’s lymphoma. Onco Nusr Forum 27: 51–59.
12. Plokker GL, Figditt DP (2003) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs 63: 803–843.
13. Chow KU, Sommerlad WD, Böhmer S, Schneider B, Seipel G, et al. (2002) Anti-CD20 antibody (IDEC-C2B8, Rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro; role of cytokines, complement, and caspases. Haematologica 87: 33–43.
14. Li M, Lin Z, Qiao C, Gen S, Lang X, et al. (2010) Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Cancer Let 294: 66–73.
15. Wu L, Wang C, Zhang D, Zhang X, Qian W, et al. (2010) Characterization of a fully human anti-CD20 monoclonal antibody for cancer therapy. J Immunol Methods 354: 210–218.
16. Bornstein GG, Queva C, Tabrizi M, van Abbe MA, Chavez C, et al. (2010) Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 28: 361–374.
17. Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs 63: 803–843.
18. Chow KU, Sommerlad WD, Böhmer S, Schneider B, Seipel G, et al. (2002) Anti-CD20 antibody (IDEC-C2B8, Rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro; role of cytokines, complement, and caspases. Haematologica 87: 33–43.
19. Li M, Lin Z, Qiao C, Gen S, Lang X, et al. (2010) Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Cancer Let 294: 66–73.
20. Wu L, Wang C, Zhang D, Zhang X, Qian W, et al. (2010) Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Let 292: 208–214.
21. Bornstein GG, Queva C, Tabrizi M, van Abbe MA, Chavez C, et al. (2010) Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 28: 361–374.
22. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359–7368.
23. Harjupää A, Junnikkala S, Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51: 634–641.
24. Banerji R, Kaita S, Flink IW, Pearson M, Young D, et al. (2003) Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo Rituximab resistance. J Clin Oncol 21: 1466–1471.
25. Amorosi A, Haﬁs S, Miliello L, Russo AE, Sousa Z, et al. (2011) Understanding Rituximab function and resistance: implications for tailored therapy. Front Biosci 16: 770–782.
26. Gaüzé D, Fudelson Z (2009) Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol 46: 2794–2800.
27. Vugmeyster Y, Howell K, Baksh A, Flores C, Canova-Davis E (2005) Effect of anti-CD20 monoclonal antibody, Rituxan, on cytokomups monkey and human B cells in a whole blood matrix. Cytometry A 62: 101–109.
28. Brueurs E, Medkova M, Savennell N, Marran D, Twarskowska M, et al. (2009) Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci U S A 106: 14195–14200.
29. Liadi I, Rozzik J, Romain G, Cooper LJ, Varadarajan N (2013) Quantitative high-throughput single-cell cytotoxicity assay for T cells. J Vis Exp: e50038.